In 2021, Yu et al. reported a series of EZH2-targeting PROTACs, including E7, which mediated a decrease of PRC2 subunits and demonstrated superior inhibition of tumor growth compared to SMIs in DLBCL cells, irrespective of EZH2 mutation status. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.